Paul  Blanchfield net worth and biography

Paul Blanchfield Biography and Net Worth

Insider of Lantheus
Paul Blanchfield serves as our Chief Commercial Officer, having joined Lantheus in January 2020.  Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion dollar P&L covering multiple rare diseases products. Prior to his time at Takeda, Mr. Blanchfield served in several different roles at Shire Plc across almost 6 years, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. In his time at Shire, Mr. Blanchfield launched multiple products, worked across nine different countries, oversaw a restructuring to increase commercial focus and reduce costs, and led efforts in M&A, corporate defense, integration, and long-term corporate and portfolio strategy. Prior to his time at Shire, Mr. Blanchfield worked at McKinsey & Company for 5 years, where he focused on health care, marketing, and sales. Mr. Blanchfield earned an MBA / MA in Education from Stanford University and an AB in Economics from Duke University.

What is Paul Blanchfield's net worth?

The estimated net worth of Paul Blanchfield is at least $5.59 million as of November 16th, 2023. Mr. Blanchfield owns 88,651 shares of Lantheus stock worth more than $5,591,219 as of April 22nd. This net worth estimate does not reflect any other investments that Mr. Blanchfield may own. Additionally, Mr. Blanchfield receives an annual salary of $1,180,000.00 as Insider at Lantheus. Learn More about Paul Blanchfield's net worth.

How old is Paul Blanchfield?

Mr. Blanchfield is currently 42 years old. There are 6 older executives and no younger executives at Lantheus. The oldest executive at Lantheus is Mr. Brian A. Markison, CEO & Director, who is 65 years old. Learn More on Paul Blanchfield's age.

What is Paul Blanchfield's salary?

As the Insider of Lantheus Holdings, Inc., Mr. Blanchfield earns $1,180,000.00 per year. The highest earning executive at Lantheus is Mr. Robert J. Marshall Jr., CFA, CFO & Treasurer, who commands a salary of $1,300,000.00 per year. Learn More on Paul Blanchfield's salary.

How do I contact Paul Blanchfield?

The corporate mailing address for Mr. Blanchfield and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Paul Blanchfield's contact information.

Has Paul Blanchfield been buying or selling shares of Lantheus?

Paul Blanchfield has not been actively trading shares of Lantheus over the course of the past ninety days. Most recently, Paul Blanchfield sold 1,500 shares of the business's stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $67.96, for a transaction totalling $101,940.00. Following the completion of the sale, the president now directly owns 88,651 shares of the company's stock, valued at $6,024,721.96. Learn More on Paul Blanchfield's trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 19 times. They sold a total of 148,672 shares worth more than $10,389,459.87. The most recent insider tranaction occured on April, 15th when CAO Andrea Sabens sold 341 shares worth more than $20,882.84. Insiders at Lantheus own 2.1% of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 4/15/2024.

Paul Blanchfield Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2023Sell1,500$67.96$101,940.0088,651View SEC Filing Icon  
8/21/2023Sell408$66.10$26,968.8090,067View SEC Filing Icon  
8/21/2023Sell408$66.10$26,968.8090,067View SEC Filing Icon  
8/18/2023Sell1,500$65.19$97,785.0090,475View SEC Filing Icon  
5/18/2023Sell1,500$97.93$146,895.0092,743View SEC Filing Icon  
3/6/2023Sell5,250$72.56$380,940.0089,101View SEC Filing Icon  
11/17/2022Sell2,432$54.79$133,249.2873,968View SEC Filing Icon  
8/18/2022Sell1,500$83.39$125,085.0076,143View SEC Filing Icon  
3/4/2022Sell3,914$49.98$195,621.72View SEC Filing Icon  
3/4/2021Sell4,061$18.40$74,722.40View SEC Filing Icon  
See Full Table

Paul Blanchfield Buying and Selling Activity at Lantheus

This chart shows Paul Blanchfield's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Read More

Today's Range

Now: $63.07
Low: $63.07
High: $64.31

50 Day Range

MA: $60.94
Low: $54.89
High: $68.26

2 Week Range

Now: $63.07
Low: $50.20
High: $100.85


652,013 shs

Average Volume

1,053,747 shs

Market Capitalization

$4.32 billion

P/E Ratio


Dividend Yield